Mark Baldry - 16 May 2025 Form 4/A - Amendment Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Commercial Officer
Issuer ticker: XFOR
Reported as of: 16 May 2025
Net transaction value: +$2,561
SEC form: 4/A - Amendment
Accepted by SEC: 03 Jun 2025, 17:01:06 UTC
Original report date: 20 May 2025
Prior SEC filing: 27 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Adam S. Mostafa, attorney-in-fact

Key filing fact

Mark Baldry filed Form 4/A - Amendment for X4 Pharmaceuticals, Inc (XFOR) on 03 Jun 2025.

Key facts

This page summarizes Mark Baldry's Form 4/A - Amendment filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jun 2025, 17:01.

Change

Previous filing in this sequence was filed on 27 Jan 2025.
Current net transaction value: +$2,561.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001644137 Primary reporting owner

Baldry Mark

Relationship: Chief Commercial Officer
Address: C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON
Signature: /s/ Adam S. Mostafa, attorney-in-fact
Signature date: 03 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Award

Transaction value: $2,561
Shares: +1,032
Change %: +4.2%
Price: $2.48
Shares after: 25,337
Date: 16 May 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended.

SEC remarks

On May 20, 2025, a Form 4 was filed on behalf of the Reporting Person which inadvertently reported a transaction that occurred on May 16, 2025 using the incorrect transaction code P in Column 3 of Table I. As shown in this amendment, this transaction is reported using transaction code A in Column 3 of Table I.